Keeping your nuclear medicine practices safe and compliant
The Australian Nuclear Medicine Traceability Program (ANMTP) assists practices administering nuclear medicine-based radionuclides to achieve regulatory compliance by providing measurement traceability to the Australian Standard. The program was developed in response to the need for radionuclide metrology within nuclear medicine practices, expressed by the Australian and New Zealand Society of Nuclear Medicine (ANZSNM).
2025 ANMTP program details
The ANMTP service includes an assessment and adjustment, if required, of dose calibrator(s) by a Radionuclide Metrologist, using any or all available radioactivity standards.
Registrations for ANMTP 2025 are currently open and will close on 3rd October 2025.
Radioactivity Standards for four radionuclides will be available in 2025:
• 600 MBq* Technetium-99m (5 mL in 10 mL Wheaton vial)
• 600 MBq* Iodine-131 capsule (Capsule in 10 mL Wheaton vial)
• 500 MBq* Iodine-123 (0.25 – 1 mL in 2 mL V-vial)
• 5 GBq* Lutetium-177 (0.5 mL in 2 mL V-vial)
*At reference time
Following recent primary standardisation and international comparison, we are pleased to introduce Iodine-123 to the program in 2025.
Benefits
- Improved accuracy and precision in the administration of radiopharmaceuticals through direct comparison with the Australian standard for radioactivity
- Assistance to meet regulatory compliance obligations (e.g. ARPANSA Safety Guide to Radiation Protection in Nuclear Medicine)
- Improved patient outcomes through ongoing accurate and reliable administration of radiopharmaceuticals
Inclusions
- An onsite visit and dose calibrator measurement assessment by an ANSTO radionuclide metrologist
- Radioactivity Standard (calibration sources)
- A measurement report
- A certificate of traceability to the Australian Standard for the supplied Radioactivity Standard